InMed Pharmaceuticals Inc. (INM)
NASDAQ: INM · Real-Time Price · USD
1.560
-0.030 (-1.89%)
At close: Jun 4, 2026, 4:00 PM EDT
1.470
-0.090 (-5.77%)
After-hours: Jun 4, 2026, 7:35 PM EDT
InMed Pharmaceuticals Revenue
InMed Pharmaceuticals had revenue of $4.94M in the twelve months ending March 31, 2026, up 285.22% year-over-year. In the fiscal year ending June 30, 2025, InMed Pharmaceuticals had annual revenue of $4.94M with 7.50% growth.
Revenue (ttm)
$4.94M
Revenue Growth
+285.22%
P/S Ratio
1.45
Revenue / Employee
$380,203
Employees
13
Market Cap
6.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 4.94M | 344.90K | 7.50% |
| Jun 30, 2024 | 4.60M | 462.17K | 11.18% |
| Jun 30, 2023 | 4.14M | 3.05M | 279.61% |
| Jun 30, 2022 | 1.09M | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 43.20M |
| Sunshine Biopharma | 35.49M |
| cbdMD | 19.98M |
| Sonoma Pharmaceuticals | 17.72M |
| China SXT Pharmaceuticals | 1.54M |
| Akanda | 836.66K |
| RedHill Biopharma | 286.00K |
| Gelteq | 270.85K |
INM News
- 3 hours ago - InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements - Newsfile Corp
- 16 days ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM) - GlobeNewsWire
- 16 days ago - InMed Pharmaceuticals Transcript: M&A announcement - Transcripts
- 16 days ago - InMed Pharmaceuticals Press release: M&A announcement - Filings
- 16 days ago - InMed Pharmaceuticals and Mentari announce merger for migraine prevention - TheFly
- 16 days ago - InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies - PRNewsWire
- 16 days ago - InMed Pharmaceuticals Amends Preferred Investment Options - Newsfile Corp
- 4 weeks ago - InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update - Newsfile Corp